Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$17,500.00
3-in-1 Nanoparticle Formulation Containing Cisplatin, Olaparib, and Nivolumab for the Treatment of Ovarian Cancer
FY 2022-23
Summary
Among gynecological cancers, ovarian cancer is the leading cause of death in women. Current treatment options include chemotherapy, with cisplatin as the most effective. Cisplatin binds to DNA, which ultimately causes cell death. However, resistance to cisplatin is the leading cause of treatment failure. An enzyme, known as poly-ADP ribose polymerase (PARP), works to repair damaged DNA. Olaparib is a small molecule that inhibits PARP, thereby preventing a resistance mechanism from occurring. Additionally, ovarian cancer cells can evade the immune system to grow uncontrollably undetected by inactivating T cells. Nivolumab, a monoclonal antibody, inhibits this interaction, restoring T cell cytotoxicity. Combining multiple drugs together can thus provide more benefits than single drug therapy. Nanomedicine is an emerging field that can further enhance combination therapy. Encapsulating two or more drugs into a single nanoparticle (NP) ensures that the desired concentration of each drug is reaching the tumors at the same time. NP delivery also prevents off target effects and degradation in the bloodstream and facilitates overlapping pharmacological profiles of drugs. However, there is currently no clinically approved NP drug formulation for the treatment of ovarian cancer. Therefore, we hypothesize that the combination of cisplatin, olaparib, and nivolumab in a single NP will improve overall survival in ovarian cancer compared to free drug alone and in combination. We plan to develop and optimize a 3-in-1 NP formulation containing cisplatin, olaparib, and nivolumab. We will test the efficacy of our NP therapy in both in vitro and in vivo models. Overall, this study will signify the importance for developing new therapeutic strategies for ovarian cancer.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
487203
Name
Durocher Emma M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
3-in-1 Nanoparticle Formulation Containing Cisplatin, Olaparib, and Nivolumab for the Treatment of Ovarian Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biomaterials; Cisplatin; Combination Therapy; Nanoparticles; Olaparib; Ovarian Cancer; Parp Inhibitor; Targeted Nanotherapeutics
Abstract
Among gynecological cancers, ovarian cancer is the leading cause of death in women. Current treatment options include chemotherapy, with cisplatin as the most effective. Cisplatin binds to DNA, which ultimately causes cell death. However, resistance to cisplatin is the leading cause of treatment failure. An enzyme, known as poly-ADP ribose polymerase (PARP), works to repair damaged DNA. Olaparib is a small molecule that inhibits PARP, thereby preventing a resistance mechanism from occurring. Additionally, ovarian cancer cells can evade the immune system to grow uncontrollably undetected by inactivating T cells. Nivolumab, a monoclonal antibody, inhibits this interaction, restoring T cell cytotoxicity. Combining multiple drugs together can thus provide more benefits than single drug therapy. Nanomedicine is an emerging field that can further enhance combination therapy. Encapsulating two or more drugs into a single nanoparticle (NP) ensures that the desired concentration of each drug is reaching the tumors at the same time. NP delivery also prevents off target effects and degradation in the bloodstream and facilitates overlapping pharmacological profiles of drugs. However, there is currently no clinically approved NP drug formulation for the treatment of ovarian cancer. Therefore, we hypothesize that the combination of cisplatin, olaparib, and nivolumab in a single NP will improve overall survival in ovarian cancer compared to free drug alone and in combination. We plan to develop and optimize a 3-in-1 NP formulation containing cisplatin, olaparib, and nivolumab. We will test the efficacy of our NP therapy in both in vitro and in vivo models. Overall, this study will signify the importance for developing new therapeutic strategies for ovarian cancer.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Durocher, Emma M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~